What it's for (Indications)
- Gliquidone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- It is primarily used when diet and exercise alone do not achieve adequate blood glucose reduction.
- Its pharmacokinetic profile, characterized by significant hepatic metabolism and predominantly biliary excretion (approximately 95% is eliminated via bile), makes it a suitable option for certain patients with mild to moderate renal impairment, where other sulfonylureas might be contraindicated or require substantial dose adjustments.
- The decision to initiate gliquidone should be based on a comprehensive assessment of the patient's overall health, glycemic targets, and potential risks, particularly hypoglycemia.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of gliquidone must be individualized based on the patient's glycemic response, tolerability, and renal/hepatic function, starting with a low dose and titrating upwards. Typically, an initial dose of 15 mg once daily, administered with breakfast, is recommended. Dosing should be initiated conservatively to minimize the risk of hypoglycemia. The daily dose can be gradually increased in increments of 15 mg at intervals of several days, if necessary, until adequate glycemic control is achieved. For daily doses exceeding 60 mg, it is advisable to divide the total daily dose and administer it with meals. The maximum recommended daily dose is generally 120 mg, although some clinical contexts may allow up to 180 mg under strict medical supervision and careful monitoring. Careful monitoring of blood glucose levels is essential during dose titration and throughout treatment. |
Safety & Warnings
Common Side Effects
- The most frequent and clinically significant adverse effect associated with gliquidone, consistent with its pharmacological class, is hypoglycemia.
- Symptoms of hypoglycemia can range from mild (e.
- g.
- , headache, dizziness, sweating, hunger, tremor, nervousness, confusion) to severe (e.
- g.
- , seizures, loss of consciousness, coma, permanent neurological damage), potentially leading to life-threatening events.
- Other reported adverse reactions include gastrointestinal disturbances such as nausea, vomiting, epigastric fullness, diarrhea, and constipation.
- Dermatological reactions like rash, pruritus, urticaria, erythema, and photosensitivity have also been observed.
- Less common but serious side effects can include transient elevations in liver enzymes, cholestatic jaundice, and hematologic abnormalities such as leukopenia, thrombocytopenia, agranulocytosis, and hemolytic anemia, especially in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- Weight gain is also a recognized class effect.
Serious Warnings
- Black Box Warning: Gliquidone is not widely marketed in the United States and therefore does not carry an FDA-mandated Black Box Warning specific to its labeling. However, clinicians prescribing gliquidone, or any sulfonylurea, must be acutely aware of serious warnings associated with the sulfonylurea class. A long-standing concern, emanating from the University Group Diabetes Program (UGDP) study with first-generation sulfonylureas (specifically tolbutamide), suggested an increased risk of cardiovascular mortality compared to treatment with diet alone or insulin. While the generalizability of these findings to all second-generation sulfonylureas like gliquidone has been debated, it underscores the need for careful patient selection and thorough evaluation of cardiovascular risk factors. The primary and most frequent serious risk remains severe hypoglycemia, which can lead to profound neurological damage, coma, and even death. Patients should be thoroughly educated on hypoglycemia prevention, recognition, and appropriate emergency management. Factors such as renal or hepatic impairment, alcohol consumption, advanced age, and concurrent use of other hypoglycemic agents significantly increase the risk of this life-threatening adverse event.
- Gliquidone, like all sulfonylureas, carries a significant risk of hypoglycemia, which can be severe and life-threatening.
- This risk is increased with inadequate caloric intake, skipped meals, prolonged or strenuous exercise, alcohol ingestion, concomitant use of other glucose-lowering agents, renal or hepatic impairment, and in elderly, debilitated, or malnourished patients.
- Patients and their caregivers must be thoroughly educated on the symptoms, prevention, and appropriate management of hypoglycemia.
- The potential for increased cardiovascular mortality with sulfonylureas has been a long-standing concern, stemming from the University Group Diabetes Program (UGDP) study with first-generation sulfonylureas (tolbutamide); while direct evidence for gliquidone is limited, clinicians should be aware of this class effect.
- Gliquidone should be used with caution in patients with hepatic impairment due to its primary metabolism by the liver, and careful monitoring of liver function is required.
- Although predominantly excreted via bile, caution is still advised in severe renal impairment.
- Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at increased risk of hemolytic anemia with sulfonylurea treatment; therefore, monitoring is recommended in susceptible individuals.
- Hypersensitivity reactions, including allergic reactions to sulfonamides, may occur.
How it Works (Mechanism of Action)
Gliquidone is a second-generation sulfonylurea oral hypoglycemic agent. Its primary mechanism of action involves stimulating insulin release from the pancreatic beta cells. It achieves this by binding to the sulfonylurea receptor 1 (SUR1) subunit of the ATP-sensitive potassium (K-ATP) channel located on the beta-cell membrane. This binding inhibits the outflow of potassium ions from the beta cell, leading to depolarization of the beta-cell membrane. Depolarization subsequently opens voltage-gated calcium channels, causing an influx of calcium ions into the cell. The increased intracellular calcium concentration triggers the exocytosis of insulin-containing granules, thereby increasing insulin secretion into the bloodstream. This enhanced insulin release helps to lower blood glucose levels in patients with type 2 diabetes who retain some pancreatic beta-cell function. Gliquidone also exerts a modest peripheral effect, potentially improving insulin sensitivity in target tissues, though its main action is pancreatic.
Commercial Brands (Alternatives)
No other brands found for this formula.